Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

被引:8
|
作者
Hess, Anja [1 ,6 ]
Gentile, Stefan D. [1 ,2 ]
Ben Saad, Amel [1 ]
Rahman, Raza-Ur [1 ]
Habboub, Tim [1 ]
Pratt, Daniel S. [1 ,3 ]
Mullen, Alan C. [1 ,2 ,4 ,5 ,7 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02115 USA
[2] Broad Inst MIT & Harvard, Klarman Cell Observ, Cambridge, MA 02142 USA
[3] Massachusetts Gen Hosp, Autoimmune & Cholestat Liver Ctr, Boston, MA USA
[4] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA
[5] Harvard Stem Cell Inst, Cambridge, MA 02138 USA
[6] Max Planck Inst Mol Genet, Dept Genome Regulat, Berlin, Germany
[7] Univ Massachusetts, Chan Med Sch, Worcester, MA 01605 USA
来源
EMBO JOURNAL | 2023年 / 42卷 / 24期
关键词
fibrosis; liver organoids; MASLD; NAFLD; single-cell RNA-sequencing; HEPATIC STELLATE CELLS; PALMITIC ACID; NONALCOHOLIC STEATOHEPATITIS; REGULATES FIBROSIS; MEDITERRANEAN DIET; RECEPTOR; EXPRESSION; DIFFERENTIATION; LIPOTOXICITY; PATHOGENESIS;
D O I
10.15252/embj.2023113898
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing cause of morbidity with limited treatment options. Thus, accurate in vitro systems to test new therapies are indispensable. While recently, human liver organoid models have emerged to assess steatotic liver disease, a systematic evaluation of their translational potential is still missing. Here, we evaluated human liver organoid models of MASLD, comparatively testing disease induction in three conditions: oleic acid, palmitic acid, and TGF-beta 1. Through single-cell analyses, we find that all three models induce inflammatory signatures, but only TGF-beta 1 promotes collagen production, fibrosis, and hepatic stellate cell expansion. In striking contrast, oleic acid ameliorates fibrotic signatures and reduces the hepatic stellate cell population. Linking data from each model to gene expression signatures associated with MASLD disease progression further demonstrates that palmitic acid and TGF-beta 1 more robustly model inflammation and fibrosis. Our findings highlight the importance of stratifying MASLD organoid models by signatures of clinical disease progression, provide a single-cell reference to benchmark future organoid injury models, and allow us to study evolving steatohepatitis, fibrosis, and HSC susceptibility to injury in a dynamic, multi-lineage human in vitro system. imageMetabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is a major cause of chronic hepatic injury and failure, however the details of its induction remain unclear. This benchmark resource reports in vitro dissection of fatty liver disease in human organoids uncovering distinct disease phenotypes triggered by specific lipids.Human pluripotent stem cell-derived liver organoids serve as models for injury related to MASLD.Palmitic acid induces inflammatory signatures while TGF-beta 1 signaling induces inflammatory and fibrotic signatures.Oleic acid reduces hepatic stellate cell numbers and suppresses collagen production.Gene expression predicting MASLD severity increases from palmitic acid to TGF-beta 1 treatment. Comprehensive dissection of fatty liver disease in human organoids uncovers unexpected phenotype heterogeneity triggered by specific fatty acids.image
引用
收藏
页数:25
相关论文
共 50 条
  • [1] Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease (vol 42, e113898, 2023)
    Hess, Anja
    Gentile, Stefan D.
    Saad, Amel Ben
    Rahman, Raza-Ur
    Habboub, Tim
    Pratt, Daniel S.
    Mullen, Alan C.
    EMBO JOURNAL, 2024, 43 (24): : 6792 - 6795
  • [2] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [3] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [4] Metabolic dysfunction-associated steatotic liver disease in adults
    不详
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [5] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [6] Metabolic dysfunction-associated steatotic liver disease in adults
    Huang, Daniel Q.
    Wong, Vincent W. S.
    Rinella, Mary E.
    Boursier, Jerome
    Lazarus, Jeffrey V.
    Yki-Jarvinen, Hannele
    Loomba, Rohit
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [7] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [8] Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stefan, Norbert
    Roden, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 : S290 - S296
  • [9] Metabolic dysfunction-associated steatotic liver disease in children
    Goyal, Nidhi P.
    Xanthakos, Stavra
    Schwimmer, Jeffrey B.
    GUT, 2025,
  • [10] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186